Latest News
See all →
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
- New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX…
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
Garching / Munich, Germany, andGrenoble, France, June 16, 2025 - ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today…
Read more
ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
Garching / Munich, Germany, June 13, 2025 -ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced…
Read more
